<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="868">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510623</url>
  </required_header>
  <id_info>
    <org_study_id>H20-00600</org_study_id>
    <nct_id>NCT04510623</nct_id>
  </id_info>
  <brief_title>Host Response Mediators in Coronavirus (COVID-19) Infection</brief_title>
  <acronym>ARBS CORONA I</acronym>
  <official_title>Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Centre for Disease Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels&#xD;
      are increased in human influenza and are associated with influenza viral load, disease&#xD;
      progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs)&#xD;
      limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit&#xD;
      viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and&#xD;
      test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine&#xD;
      whether there is a correlation between taking ARBs and clinical outcomes in these patients.&#xD;
&#xD;
      Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent&#xD;
      weeks. We include these in our observational analysis to help generate an understanding of&#xD;
      COVID-19 presentation and blood biomarker characterization of disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine whether angiotensin II receptor blockers (ARBs) decrease severity or&#xD;
      mortality in hospitalized COVID-19 infected adults.&#xD;
&#xD;
      Main Hypothesis: Modulation of ACE2 by ARBs decreases the need for hospitalization, severity&#xD;
      (need for ventilation, vasopressors, extracorporeal membrane oxygenation or renal replacement&#xD;
      therapy) or mortality of hospitalized COVID-19 infected adults.&#xD;
&#xD;
      Secondary Hypotheses:&#xD;
&#xD;
        -  Plasma angiotensin I and II and other biomarker levels are associated with effectiveness&#xD;
           of ARBs in hospitalized COVID-19 adults&#xD;
&#xD;
        -  Modulation of ACE2 by angiotensin type I receptor blockers is associated with decreased&#xD;
           rate of hospitalization for COVID-19&#xD;
&#xD;
        -  In patients already on ARBs when they are hospitalized continuing ARBs is associated&#xD;
           with decreased World Health Organization (WHO) COVID-19 ordinal outcome scale&#xD;
&#xD;
      Justification: The COVID-19 epidemic continues to grow exponentially affecting over 71,429&#xD;
      individuals with 1775 deaths (February 17, 2020), mostly in China but also in other&#xD;
      countries. The population mortality rate is 2% (lower than SARS (10%) and MERS (36%) but is&#xD;
      10% in hospitalized and 24% in ICU-admitted COVID-19 patients in China. Recent data from&#xD;
      China (not yet public domain) suggest ICU mortality is higher (J. Marshall personal&#xD;
      communication). Interventions to date include quarantine, isolation and usual clinical care.&#xD;
      There are no proven antiviral or host modulating interventions for COVID-19. Notably,&#xD;
      critically ill COVID-19 patients have similar mortality rates as sepsis and acute respiratory&#xD;
      distress syndrome. Cohort studies have shown that patients already on angiotensin-converting&#xD;
      enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have lower sepsis&#xD;
      mortality. Angiotensin II worsens lung injury in influenza models because ACE2 is&#xD;
      downregulated in H1N1, H5N1, H7N9, and SARS viral infections leading to increased angiotensin&#xD;
      II. Angiotensin II levels are increased in human influenza and are associated with influenza&#xD;
      viral load, disease progression and mortality. Preliminary data shows ARBs limits lung injury&#xD;
      in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and&#xD;
      organ injury in COVID-19.&#xD;
&#xD;
      Research Design:&#xD;
&#xD;
      Prospective clinical chart review: we will collect clinical data on the participant&#xD;
      throughout their hospital stay. Includes collection of baseline characteristics such as age,&#xD;
      sex, heart rate, respiratory rate, temperature, blood pressure, SaO2, respiratory&#xD;
      (PaO2/FiO2), renal (creatinine) and hepatic (bilirubin) function, use of oxygen,&#xD;
      vasopressors, ventilation and RRT. They will be followed daily throughout their hospital&#xD;
      stay, until death or discharge. Using left over clinical blood collected upon admission to&#xD;
      hospital, plasma angiotensin I and II and other biomarker levels will be measured in our&#xD;
      research laboratories.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 WHO ordinal scale</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Organ Dysfunction</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>29 days or less (may be discharged from critical care before day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital/ICU length of stay</measure>
    <time_frame>29 days or less (may be discharged before day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>29 days or less (may be discharged from critical care before day 28)</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV2</condition>
  <arm_group>
    <arm_group_label>COVID-19 Patients on ARBs</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Patients on ACE inhibitors</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Patients on ARBs or ACE inhibitors</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Patients not on ARBs or ACE inhibitors</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ARBs and/or ACE inhibitors</intervention_name>
    <description>This is an observational study only.</description>
    <arm_group_label>COVID-19 Patients on ACE inhibitors</arm_group_label>
    <arm_group_label>COVID-19 Patients on ARBs</arm_group_label>
    <arm_group_label>COVID-19 Patients on ARBs or ACE inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>This is an observational study only.</description>
    <arm_group_label>COVID-19 Patients not on ARBs or ACE inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult hospitalized patients with confirmed COVID-19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals over 18 years of age who have confirmed COVID-19 infection (according to&#xD;
             local hospital or provincial laboratories clinically approved laboratory testing for&#xD;
             COVID-19).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Russell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Paul's Hospital, Center for Heart and Lung Innovation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Puneet Mann, MSc</last_name>
    <phone>604 682 2344</phone>
    <phone_ext>64734</phone_ext>
    <email>pmann7@providencehealth.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynda Lazosky</last_name>
    <phone>604-682-2344</phone>
    <phone_ext>64886</phone_ext>
    <email>llazosky@providencehealth.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary - Foothills</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Winston, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Joffe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksa Rewa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Surrey Memorial Hospital</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory Haljan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Pauls Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puneet Mann, MSc</last_name>
      <phone>604 682 2344</phone>
      <phone_ext>64734</phone_ext>
      <email>pmann7@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>James A Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sweet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queens University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Maslove, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataly Farshait</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison McGeer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Marshall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Fowler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Lamontagne, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jim Russell</investigator_full_name>
    <investigator_title>Study-Wide Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ARBs</keyword>
  <keyword>angiotensin II type 1 receptor blocker</keyword>
  <keyword>ACEi</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>coronavirus</keyword>
  <keyword>Multisite</keyword>
  <keyword>Canada</keyword>
  <keyword>Observational</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

